STOCKHOLM, April 26, 2018 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today informs that data from the initial phase IIa study of MIV-711, which demonstrated disease-modifying activity in patients with
Growth Capitalist (https://growthcapitalist.com/2018/04/medivir-ab-data-from-the-miv-711-initial-phase-iia-study-will-be-presented-at-the-oarsi-world-congress-on-april-27/)
STOCKHOLM, April 26, 2018 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today informs that data from the initial phase IIa study of MIV-711, which demonstrated disease-modifying activity in patients with